Abstract
In various human cancers, dysfunction of the E-cad-herin-catenin complex is associated with a decrease in cellular and tissue differentiation, and with higher invasive and metastatic potentials. The objective of this study was to investigate E-cadherin and α-catenin expression in superficial noninvasive papillary TCC and invasive TCC, and correlate these results with pathological and clinical parameters. We have used immunohistochemistry to localize Ecadherin and α-catenin in 56 formalin-fixed, paraffin-embedded tissue blocks from 41 patients with superficial bladder cancer and 15 with invasive bladder cancer. The 46 male and 10 female patients had a mean age of 67 years, with range of 40 to 82 years. The mean follow-up time was 33.4 (range 5–120) months. Tumor grade 1:2:3 ratios were 5:32:19. In superficial bladder tumor, abnormal expression of E-cadherin and a-catenin was demonstrated in 37 and 71% of the tumors, respectively. In advanced bladder tumor, abnormal expression of E-cadherin and a-catenin was demonstrated in 80 and 100% of the tumors, respectively. Differences in expression of E-cadherin and α-catenin could be discerned between superficial and advanced bladder tumors (p=0.004, p=0.024, respectively). However, the association between E-cadherin and α-catenin expression and tumor grade was not statistically significant (p>0.05). In addition, the expression of E-cadherin and α-catenin did not correlate with tumor number and size (p>0.05). We have demonstrated that abnormal expression of E-cadherin and/or α-catenin occurs in more than 85% of bladder carcinomas and correlates significantly only with advanced stage. Nevertheless, these observations need to be confirmed in larger prospective clinical studies.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abel PD, Henderson D, Bennett M.K, et al: Differing interpretations by pathologists of the pT category and grade of transitional cell cancer of the bladder. Br J Urol 623: 39–42, 1988.
Bringuier PP, Giroldi LA, Umbas R, et al: Mechanisms associated with abnormal E-cadherin immunoreactivity in human bladder tumors. Int J Cancer 83: 591–595, 1999.
Bringuier PP, Umbas R, Schaafsma HE, et al: Decreased Ecadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 53: 3241–3245, 1993.
Fujisawa M, Miyazaki J, Takechi Y, et al: The significance of Ecadherin in transitional-cell carcinoma of the human urinary bladder. World J Urol 14: 12–15, 1996.
Giroldi LA, Schalken JA: Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. Cancer Metastasis Rev 12: 29–37, 1993.
Hirano S, Kimoto N, Shimoyama Y, et al: Identification of a neural alpha-cateuin as a key regulator of cadherin function and multicellular organization. Cell 70: 293–301, 1992.
International Union Against Cancer, Hermanek P, Sobin LH: (eds) TNM Classification of Malignant Tumors, 5th ed, Springer-Verlag, Germany, 1997.
Koksal IT, Ozcan F, Kilicaslan I, Tefekli A: Expression of E-cadherin in prostate cancer in formalin-fixed, paraffinembedded tissues: correlation with pathological features. Pathology 34: 233–238, 2002.
Krishnadath KK, Tilanus HW, van Blankenstein M, et al: Reduced expression of the cadherin-cateniu complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol 182: 331–338, 1997.
Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 49: 8–31, 1999.
Lipponen PK: Review of cytometric methods in the assessment of prognosis in transitional cell bladder cancer. Eur Urol 21: 177–183, 1992.
Lipponen PK, Eskelinen MJ: Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol 121:303–308, 1995.
Lopez-Beltran A, Croghan GA, Croghan I, et al: Prognostic factors in survival of bladder cancer. Cancer 70: 799–807, 1992
Mansouri A, Spurr N, Goodfellow PN, Kemler R: Characterization and chromosomal localization of the gene encoding the human cell adhesion molecule uvomorulin. Differentiation 38: 67–71, 1988.
Mialhe A, Louis J, Montlevier S, et al: Expression of E-cadherin and alpha-, beta- and gamma-catenins in human bladder carcinomas: are they good prognostic factors? Invasion Metastasis 17: 124–137, 1997.
Mialhe A, Louis J, Pasquier D, et al: Expression of three cell adhesion molecules in bladder carcinomas: correlation with pathological features. Anal Cell Pathol 13: 125–136, 1997.
Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al: Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 163: 73–78, 2000.
Mostofi FK, Sobin LH, Torloni H: Histological typing of urinary bladder tumours, In: International Histologicai Classification of Tumors, 10. World Health Organisation, Geneva, 1973.
Narayana AS, Loening SA, Slymen DJ, Culp DA: Bladder cancer: factors affecting survival. J Urol 130: 56–60, 1983.
Oka H, Shiozaki H, Kobayashi K, et al: Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 53: 1696–1701, 1993.
Otto T, Birchmeier W, Schmidt U, et al: Inverse relation of Ecadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res 54: 3120–3123, 1994.
Ozawa M, Baribault H, Kemler R: The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J 8: 1711–1717, 1989.
Ozawa M, Ringwald M, Kemler R: Uvomoralin-catenin complex formation is regulated by a specific domain in the cytoplasmic region of the cell adhesion molecule. Proc Natl Acad Sci USA 8742: 46–50, 1990.
Ross JS, del Rosario AD, Figge HL, et al: E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder. Hum Pathol 26: 940–944, 1995.
Shimoyama Y, Nagafuchi A, Fujita S, et al: Cadherin dysfunction in a human cancer cell line: possible involvement of loss of alpha-catenin expression in reduced cell-cell adhesiveness. Cancer Res 52: 5770–5774, 1992.
Shimazui T, Schalken JA, Giroldi LA, et al: Prognostic value of cadherin-associated molecules (alpha-, beta-, and gammacatenins and pl20cas) in bladder tumors. Cancer Res 56: 4154–4158, 1996.
Soloway MS: Intravesical therapy for bladder cancer. Urol Clin North Am 15: 661–669, 1988.
Syrigos KN, Harrington K, Waxman J, et al: Altered gammacatenin expression correlates with poor survival in patients with bladder cancer. J Urol 160: 1889–1893, 1998.
Syrigos KN, Krausz T, Waxman J, et al: E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival. Int J Cancer 64: 367–370, 1995.
Takaishi M: Cadherin cell adhesion receptor as a morphogenetic regulator. Science 251:1451–1455, 1991.
Thrasher JB, Crawford ED: Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol 149: 957–972, 1993.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koksal, I.T., Ates, M., Danisman, A. et al. Reduced E-cadherin and α-catenin expressions have no prognostic role in bladder carcinoma. Pathol. Oncol. Res. 12, 13–19 (2006). https://doi.org/10.1007/BF02893426
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02893426